Cjc Dac Vs No Dac

Direct Comparison: CJC-1295 With DAC vs. Without DAC (Mod GRF 1-29)

In direct comparative assays, the primary operational difference when evaluating cjc dac vs no dac is half-life and circulating duration. CJC-1295 with DAC features a reactive maleimido-propionic acid moiety that covalently conjugates to circulating serum albumin upon administration in vivo, extending its biological half-life to approximately 6 to 8 days in rodent models. Conversely, CJC-1295 without DAC (commonly designated as Modified GRF 1-29) lacks this conjugate group, exhibiting a rapid clearance rate with an elimination half-life of roughly 30 minutes.

This structural modification alters the downstream endocrine profile observed in preclinical research. CJC-1295 with DAC promotes sustained, continuous stimulation of pituitary somatotrophs, raising baseline growth hormone (GH) and insulin-like growth factor 1 (IGF-1) concentrations over prolonged periods. In contrast, Mod GRF 1-29 induces acute, pulsatile spikes in GH secretion that closely mimic endogenous mammalian GHRH release dynamics when introduced alongside growth hormone secretagogues.

Chemical Structure and Molecular Modifications

To understand the mechanistic diverge between these two peptides, researchers must examine their primary amino acid sequences and structural modifications. Both peptides are synthetic analogues of the N-terminal 29-amino-acid fragment of endogenous Growth Hormone-Releasing Hormone (GHRH 1-29), which represents the minimal functional sequence required to bind and activate the GHRH receptor (GHRH-R).

Mod GRF 1-29 (CJC-1295 without DAC) incorporates four specific amino acid substitutions to resist rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV). These substitutions—specifically at positions 2 (D-Ala), 8 (Ala), 15 (Gln), and 27 (Leu)—stabilize the peptide backbone against enzymatic degradation compared to native GHRH 1-29 (Sermorelin). However, despite these substitutions, small unbound peptides remain subject to rapid renal clearance and systemic degradation.

CJC-1295 with DAC builds upon the tetrasubstituted Mod GRF 1-29 structure by adding a Lysine residue at the C-terminus, which acts as a linker for the maleimidopropionic acid (DAC) group. The bi-functional DAC linker selectively reacts with the free thiol group of Cys34 on circulating serum albumin, creating a high-molecular-weight complex that evades renal filtration and enzymatic breakdown.

Pharmacokinetics and Receptor Signaling Kinetics

The pharmacokinetic profile of CJC-1295 without DAC allows for tight temporal control in experimental setups. Following administration in animal models, plasma concentrations of Mod GRF 1-29 peak rapidly and decay quickly. This brief receptor engagement window triggers an immediate release of pre-synthesized GH from anterior pituitary vesicles without desensitizing the GHRH-R or altering long-term receptor density.

Conversely, CJC-1295 with DAC exhibits an extended pharmacokinetic profile characterized by persistent plasma concentration plateaus. Preclinical data indicate that continuous activation of the GHRH receptor by albumin-bound CJC-1295 maintains elevated transcripts of GH mRNA and results in steady elevation of total daily GH output. Research models examining long-term somatotrophic axis modulation frequently utilize this variant to eliminate the requirement for repeated daily dosing regimens.

Researchers evaluating receptor desensitization kinetics should note that while long-acting GHRH agonists maintain IGF-1 elevations, prolonged receptor occupancy can alter natural pulsatile architecture. Consequently, choice of peptide often depends on whether an assay requires episodic physiological stimulation or constant metabolic signaling.

Preclinical Findings: Pulsatile vs. Continuous GH Amplification

In vivo rodent literature demonstrates distinct physiologic responses depending on whether CJC-1295 with or without DAC is introduced. Investigations examining pulsatile endocrine dynamics demonstrate that Mod GRF 1-29 works synergistically with ghrelin receptor agonists. When co-administered with compounds such as Ipamorelin or GHRP-6, Mod GRF 1-29 produces a synergistic release of GH that exceeds the additive sums of either peptide administered in isolation.

Studies measuring circulating IGF-1 concentrations show that CJC-1295 with DAC drives a continuous, dose-dependent rise in serum IGF-1 levels in rodent models, remaining elevated for up to two weeks post-single administration. This sustained elevation makes the DAC-containing variant a preferred tool in long-term catabolic model research, muscle wasting assays, and tissue repair studies where continuous growth factor presence is required.

Conversely, studies focused on pituitary safety, physiological pulse amplitude, and circadian rhythm interaction generally favor CJC-1295 without DAC. Because its clearance matches the natural physiological pulse duration, researchers can study discrete metabolic windows without altering baseline baseline homeostatic feedback loops.

Comparative Overview with Other GHRH Analogues

Understanding where CJC-1295 variants fit within the broader landscape of GHRH research compounds is essential for prospective trial design. Native GHRH 1-29 derivatives, such as those evaluated in Sermorelin research studies, possess an extremely short half-life (roughly 8 to 12 minutes) due to rapid DPP-IV inactivation. Mod GRF 1-29 extends this window to 30 minutes via tetrasubstitution, presenting an optimized candidate for short-acting secretagogue combinations.

Other long-acting analogues, such as Tesamorelin, feature a trans-3-hexenoic acid modification attached to the N-terminal trans-sequence of GHRH 1-44. While Tesamorelin demonstrates enhanced stability and specific potency in lipid metabolism models, CJC-1295 with DAC relies on covalent albumin binding for an even broader half-life window. Investigators selecting between these options must weigh half-life requirements against specific receptor target profiles available in the PX1 research catalogue.

Reconstitution, Buffer Selection, and Laboratory Handling

Proper handling and reconstitution protocols are vital to maintaining peptide integrity and preventing premature degradation of both CJC-1295 variants in laboratory settings. Both compounds are typically supplied as lyophilized cake or powder and must be handled under aseptic laboratory conditions.

Reconstitution should be performed using sterile Bacteriostatic Water (0.9% Benzyl Alcohol) or sterile physiological saline depending on assay sensitivity to preservative agents. The reconstituting solvent should be injected gently along the inner glass vial wall to prevent shear stress degradation. Vials must be swirled softly rather than vortexed or vigorously shaken.

Because the DAC moiety contains a reactive maleimide functional group, exposure to nucleophilic buffers or pH conditions outside the optimal range (pH 5.0–7.0) prior to assay introduction can cause premature cross-linking or hydrolytic cleavage of the DAC group. Stock solutions should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles, which compromise peptide primary structure and induce aggregation.

Storage and Stability Specifications

Lyophilized CJC-1295 (with or without DAC) should be stored in a dry, dark environment at -20°C for short-to-medium term storage, or at -80°C for long-term preservation. Under these conditions, the lyophilized powder maintains biochemical stability for up to 24 months from the date of synthesis.

Once reconstituted, aqueous solutions of Mod GRF 1-29 and CJC-1295 DAC should be refrigerated at 2°C to 8°C and evaluated within 14 to 28 days. Prolonged liquid storage, particularly at room temperature, leads to deamidation of glutamine residues and peptide bond cleavage. Detailed storage metrics and stability data across various temperature ranges can be found within the PX1 Research Library.

Analytical Quality Verification: COA, HPLC, and Mass Spectrometry

To ensure reproducible data across cell culture and animal models, researchers must verify supplier quality standards prior to purchasing research peptides. Impurities, peptide fragments, or incorrect sequence synthesis can obscure experimental outcomes and alter binding kinetics.

PX1 Research enforces stringent analytical testing protocols for every production lot. Every batch of CJC-1295 with DAC and CJC-1295 without DAC undergoes rigorous testing in ISO 17025 accredited facilities located in the United States. Analytical verification includes:

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Ensures purity levels equal to or exceeding 99.0%, confirming the absence of truncated sequences or residual processing reagents. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Verifies exact molecular weight and confirms correct chemical structure, including intact incorporation of the DAC moiety when present. 3. Endotoxin Testing (LAL Assay): Guarantees bacterial endotoxin levels remain below 0.1 EU/mg, preventing confounding inflammatory responses in sensitive cell lines or rodent assays.

Every product shipped from PX1 Research facilities in California and Arizona includes a lot-specific Certificate of Analysis (COA). Principal investigators and laboratory buyers interested in volume procurement can review bulk specifications on our wholesale lab account platform.